Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Prospective, Exploratory II Trial

NCT06693128 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06693128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06693128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Prospective, Exploratory II Trial
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 21, 2024
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastric and gastroesophageal junction (gej) adenocarcinoma